PT2581078E - Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação - Google Patents

Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação Download PDF

Info

Publication number
PT2581078E
PT2581078E PT12189690T PT12189690T PT2581078E PT 2581078 E PT2581078 E PT 2581078E PT 12189690 T PT12189690 T PT 12189690T PT 12189690 T PT12189690 T PT 12189690T PT 2581078 E PT2581078 E PT 2581078E
Authority
PT
Portugal
Prior art keywords
sae
composition
preparation
methods
sulfoalkyl ether
Prior art date
Application number
PT12189690T
Other languages
English (en)
Inventor
Gerold L Mosher
Douglas B Hecker
James D Pipkin
Original Assignee
Cydex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37968086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2581078(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cydex Pharmaceuticals Inc filed Critical Cydex Pharmaceuticals Inc
Publication of PT2581078E publication Critical patent/PT2581078E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D1/00—Evaporating
    • B01D1/16—Evaporating by spraying
    • B01D1/18—Evaporating by spraying to obtain dry solids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PT12189690T 2005-10-26 2005-10-26 Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação PT2581078E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/038933 WO2007050075A1 (en) 2005-10-26 2005-10-26 Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof

Publications (1)

Publication Number Publication Date
PT2581078E true PT2581078E (pt) 2015-03-10

Family

ID=37968086

Family Applications (5)

Application Number Title Priority Date Filing Date
PT12189690T PT2581078E (pt) 2005-10-26 2005-10-26 Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação
PT05856927T PT1945228E (pt) 2005-10-26 2005-10-26 Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação
PT151657376T PT2952197T (pt) 2005-10-26 2005-10-26 Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação
PT111611257T PT2335707E (pt) 2005-10-26 2005-10-26 Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação
PT121896872T PT2583668E (pt) 2005-10-26 2005-10-26 Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação

Family Applications After (4)

Application Number Title Priority Date Filing Date
PT05856927T PT1945228E (pt) 2005-10-26 2005-10-26 Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação
PT151657376T PT2952197T (pt) 2005-10-26 2005-10-26 Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação
PT111611257T PT2335707E (pt) 2005-10-26 2005-10-26 Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação
PT121896872T PT2583668E (pt) 2005-10-26 2005-10-26 Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação

Country Status (22)

Country Link
US (1) US8049003B2 (pt)
EP (5) EP2583668B1 (pt)
JP (1) JP5465432B2 (pt)
KR (1) KR101152886B1 (pt)
CN (1) CN101365459B (pt)
AT (1) ATE504305T1 (pt)
AU (1) AU2005337613B2 (pt)
BR (1) BRPI0520654B8 (pt)
CA (2) CA2632211C (pt)
CY (3) CY1116080T1 (pt)
DE (1) DE602005027415D1 (pt)
DK (5) DK2952197T3 (pt)
ES (5) ES2542893T3 (pt)
HK (4) HK1158978A1 (pt)
HU (2) HUE035181T2 (pt)
IL (3) IL191081A (pt)
LT (1) LT2952197T (pt)
MX (1) MX348982B (pt)
PL (4) PL2335707T3 (pt)
PT (5) PT2581078E (pt)
SI (2) SI2335707T1 (pt)
WO (1) WO2007050075A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061088A1 (en) * 2003-12-22 2005-07-07 Finlay Warren H Powder formation by atmospheric spray-freeze drying
RU2006141358A (ru) * 2004-04-23 2008-05-27 Сайдекс, Инк. (Us) Препаративная форма для ингалятора сухого порошка, содержащая простой сульфоалкиловый эфир циклодекстрина
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
WO2009018069A2 (en) * 2007-07-30 2009-02-05 Cydex Pharmaceuticals, Inc Mixtures of cyclodextrin derivatives
US8501740B2 (en) * 2007-10-09 2013-08-06 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
KR101868117B1 (ko) 2010-08-05 2018-06-18 시가 테크놀로지스, 인크. Ｓｔ­246 액체 제형 및 방법
ES2672238T3 (es) 2011-01-26 2018-06-13 Allergan, Inc. Composición androgénica para el tratamiento de una afección oftálmica
KR101916010B1 (ko) * 2011-04-06 2018-11-08 다우 글로벌 테크놀로지스 엘엘씨 신규한 폴리사카라이드 유도체 및 제형
EP4083075A1 (en) * 2012-02-15 2022-11-02 CyDex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
CN104704007A (zh) 2012-02-28 2015-06-10 锡德克斯药物公司 烷基化环糊精组合物及其制备和使用方法
US10040872B2 (en) 2012-10-22 2018-08-07 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
CN104902876B (zh) * 2012-11-30 2018-01-19 葛兰素史克公司 新型药物组合物
EP3183295B1 (en) 2014-08-22 2023-08-02 CyDex Pharmaceuticals, Inc. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
MX2017011966A (es) 2015-03-19 2018-06-06 Cydex Pharmaceuticals Inc Composiciones que contienen silimarina y sulfoalquil eter ciclodextrina y metodos de uso de las mismas.
EP3097962B1 (de) * 2015-05-29 2020-05-13 Symrise AG Vorrichtung zur herstellung von sprühgetrockneten agglomeraten
WO2018071547A1 (en) * 2016-10-11 2018-04-19 Aucta Pharmaceuticals Powder for oral suspension containing lamotrigine
AU2018263924A1 (en) 2017-05-03 2019-11-21 Cydex Pharmaceuticals, Inc. Composition containing cyclodextrin and busulfan
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
EP4168426A1 (en) 2020-06-18 2023-04-26 The University of Bristol Fatty acid complexes of coronavirus spike protein and their use
WO2022029334A1 (en) 2020-08-07 2022-02-10 Gbiotech S.À.R.L. Combination therapies for treating coronavirus infection
IL308250A (en) 2021-05-06 2024-01-01 Spepharm Ag Pharmaceutical formulations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
EP0163836B1 (de) 1984-04-07 1988-10-12 Bayer Ag Verfahren und Vorrichtung zur Herstellung von Granulaten
US4920214A (en) 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
ES2073507T3 (es) 1989-04-12 1995-08-16 Procter & Gamble Composiciones de productos solidos de consumo que contienen complejos con ciclodextrina en forma de pequeñas particulas.
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0710673A3 (en) 1990-05-21 1996-08-07 Toppan Printing Co Ltd Derivatives of cyclodextrins
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
IL111184A (en) 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
FR2735136B1 (fr) * 1995-06-08 1997-08-14 Roquette Freres Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
US5935941A (en) 1997-10-24 1999-08-10 Pitha; Josef Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
EP0889056B1 (en) * 1997-07-01 2006-04-12 Pfizer Products Inc. Process for making a cyclodextrin
CA2320772A1 (en) 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
MA25590A1 (fr) 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
AUPR272901A0 (en) * 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
FR2821844B1 (fr) 2001-03-08 2003-05-23 Roquette Freres Procede de preparation d'une beta-cyclodextrine directement compressible, et beta-cyclodextrine directement compressible ainsi obtenue
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20030028014A1 (en) 2001-04-26 2003-02-06 Chris Sikorski Agglomerated modified cyclodextrin and process for making same
DE10240698A1 (de) 2002-09-04 2004-03-18 Symrise Gmbh & Co. Kg Cyclodextrinpartikel
RU2006118802A (ru) * 2003-10-31 2007-12-10 Дзе Юниверсити Оф Канзас (Us) Сульфоалкилэфирные-алкилэфирные производные циклодекстрина
MX348041B (es) * 2003-12-31 2017-05-25 Cydex Pharmaceuticals Inc Formulación inhalante que contiene éter sulfoalquilico-ciclodextri na y un corticosteroide.
RU2006141358A (ru) * 2004-04-23 2008-05-27 Сайдекс, Инк. (Us) Препаративная форма для ингалятора сухого порошка, содержащая простой сульфоалкиловый эфир циклодекстрина
BRPI0513455A (pt) 2004-07-22 2008-05-06 Pfizer Prod Inc formulação para mascaramento de sabor compreendendo o fármaco em uma forma de dissolução retardada e/ou ciclodextrina em uma forma de dissolução melhorada
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20060194762A1 (en) 2004-12-23 2006-08-31 Olaf Reer Composition comprising an epothilone and methods for producing a composition comprising an epothilone
US7629331B2 (en) * 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions

Also Published As

Publication number Publication date
DE602005027415D1 (de) 2011-05-19
PL2335707T3 (pl) 2015-10-30
HK1158978A1 (en) 2012-07-27
DK2581078T3 (en) 2015-03-02
BRPI0520654A2 (pt) 2009-05-19
AU2005337613A1 (en) 2007-05-03
HK1218509A1 (zh) 2017-02-24
KR101152886B1 (ko) 2012-07-09
EP2335707A1 (en) 2011-06-22
ES2634670T3 (es) 2017-09-28
IL191081A (en) 2016-03-31
MX348982B (es) 2017-07-06
EP1945228B1 (en) 2011-04-06
IL244130A0 (en) 2016-04-21
ES2532374T3 (es) 2015-03-26
HK1184070A1 (en) 2014-01-17
DK1945228T4 (da) 2015-01-12
PL2952197T3 (pl) 2017-09-29
HUE035181T2 (hu) 2018-05-02
PT2583668E (pt) 2015-01-05
EP2583668B1 (en) 2014-10-08
CY1116517T1 (el) 2017-03-15
CA2928065A1 (en) 2007-05-03
DK2952197T3 (en) 2017-08-07
JP5465432B2 (ja) 2014-04-09
IL269619A (en) 2019-11-28
US20090011037A1 (en) 2009-01-08
SI2335707T1 (sl) 2015-09-30
ES2542893T3 (es) 2015-08-12
CA2632211C (en) 2016-07-05
PT2335707E (pt) 2015-09-10
PT2952197T (pt) 2017-07-28
EP1945228A1 (en) 2008-07-23
EP2952197A1 (en) 2015-12-09
PT1945228E (pt) 2011-07-13
KR20080063526A (ko) 2008-07-04
BRPI0520654B8 (pt) 2021-05-25
ES2364491T5 (es) 2015-02-19
DK2583668T3 (en) 2015-01-19
JP2009513773A (ja) 2009-04-02
ES2364491T3 (es) 2011-09-05
DK2335707T3 (en) 2015-08-10
IL269619B (en) 2020-07-30
IL244130B (en) 2020-06-30
WO2007050075A1 (en) 2007-05-03
EP2583668A1 (en) 2013-04-24
CY1116080T1 (el) 2017-02-08
ES2526903T3 (es) 2015-01-16
EP2581078B1 (en) 2014-12-10
SI2952197T1 (sl) 2017-09-29
PL2583668T3 (pl) 2015-05-29
CN101365459B (zh) 2011-11-30
US8049003B2 (en) 2011-11-01
PL2581078T3 (pl) 2015-07-31
AU2005337613B2 (en) 2011-04-28
EP1945228A4 (en) 2010-04-07
EP1945228B9 (en) 2015-03-11
ATE504305T1 (de) 2011-04-15
CA2632211A1 (en) 2007-05-03
BRPI0520654B1 (pt) 2020-08-11
EP2581078A1 (en) 2013-04-17
HK1184383A1 (en) 2014-01-24
CY1119471T1 (el) 2018-03-07
IL191081A0 (en) 2009-08-03
EP2335707B1 (en) 2015-05-06
LT2952197T (lt) 2017-08-25
DK1945228T3 (da) 2011-07-25
CN101365459A (zh) 2009-02-11
EP1945228B2 (en) 2014-11-05
CA2928065C (en) 2019-10-15
EP2952197B1 (en) 2017-04-26
HUE025315T2 (en) 2016-02-29

Similar Documents

Publication Publication Date Title
IL269619B (en) Preparations of sulfoalkyl other than cyclodextrin and methods for their preparation
WO2007146491A3 (en) Flowable particulates
WO2007106436A3 (en) Photoactive compounds and compositions and uses thereof
BRPI0909787A2 (pt) composição de moldagem termoplástica, usos da combinação de polieteraminas com óxidos amorfos, e de composições de moldagem trermoplásticas, fibra, folha ou moldagem, e, combinação dos componentes.
IL205966A0 (en) Oligomer-tricyclic conjugates, compositions comprising the same and uses thereof
EA200800099A1 (ru) Композиции наночастиц мегестрола
WO2008112277A3 (en) Compositions and methods for treating cancer
WO2007128639A3 (en) Novel hydrophobically modified cationic polymers and personal care compositions thereof
WO2007080323A3 (fr) Suspension aqueuse stable de nanotubes de carbone
TW200712129A (en) Silicone material having outstanding viscosity stability
IL208567A0 (en) Oligomer-aryloxy-substituted propanamine conjugates, compositions comprising the same and uses thereof
MX2021006926A (es) Composiciones de eter sulfoalquilico-ciclodextrina y metodos de preparacion de las mismas.
WO2006023882A3 (en) Anti-perspirant compositions with improved properties
WO2009031026A3 (en) Lamivudine-cyclodextrin complex
HK1166610A1 (en) Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
Pfaendner Additives Now and in the Future
UA29280U (en) Nanometal aquachelate
TW200609213A (en) Aminocyclohexyl ether compounds and uses thereof
GEP20104890B (en) Polymer concrete